https://nl.marketscreener.com/koers/aandeel/THERATECHNOLOGIES-INC-1411917/nieuws/Theratechnologies-Inc-Ibalizumab-toont-kosteneffectiviteit-aan-als-toevoeging-aan-de-routinematige-45111509/?utm_source=telegram&utm_medium=social&utm_campaign=share